Drug – bio-affecting and body treating compositions – Conjugate or complex of monoclonal or polyclonal antibody,... – Conjugated via claimed linking group – bond – chelating agent,...
Patent
1994-02-04
1998-06-02
Eisenschenk, Frank C.
Drug, bio-affecting and body treating compositions
Conjugate or complex of monoclonal or polyclonal antibody,...
Conjugated via claimed linking group, bond, chelating agent,...
4241841, 4241851, 5303871, 5303873, 53038875, 530866, 530867, 530868, C07K 1628, C07K 1900, A61K 39395
Patent
active
057595461
ABSTRACT:
A method for the selective depletion of activated CD4.sup.+ T-cells in vivo by using immunotoxins comprising the OX-40 antibody conjugated to a toxic molecule (such as Ricin-A chain). The administration of these specific immunotoxins is used therapeutically to deplete autoimmune reactive CD4.sup.+ T-cells which have been implicated in diseases including Multiple Sclerosis, Rheumatoid Arthritis, Sarcoidosis, and Autoimmune Uveitis. This type of therapy is also beneficial for eradicating CD4.sup.+ T-cell lymphomas and alloreactive CD4.sup.+ T-cells involved with a transplantation reaction. The use of the human form of the OX-40 antibody will also help in the early diagnosis of all the diseases mentioned above.
REFERENCES:
patent: 4590071 (1986-05-01), Scannon et al.
patent: 4664911 (1987-05-01), Uhr et al.
patent: 4681760 (1987-07-01), Fathman
patent: 4731244 (1988-03-01), Talle et al.
patent: 4867973 (1989-09-01), Goers et al.
patent: 5045451 (1991-09-01), Uhr et al.
patent: 5057313 (1991-10-01), Shih et al.
patent: 5057598 (1991-10-01), Pollack et al.
patent: 5091177 (1992-02-01), Hellstrom et al.
patent: 5167956 (1992-12-01), Neville et al.
Miura et al., "Molecular Cloning and Characterization of a Novel Glycoprotein, gp34, That Is Specifically Induced by the Human T-Cell Leukemia Virus Type I Transactivator p40.sup.tax, "Mol. Cell. Biol. 11:1313-1325 (1991).
W. Godfrey et al., `Molecular cloning of a cDNA encoding the human homolog of the rat OX-40 antigen`, p. 253, Tissue Antigens, vol. 42, No. 4, Oct. 1993, Copenhagen, Denmark.
S. Hamilton-Dutoit et al., `An immunohistological analysis of the mAb in the activation antigen panel`, p. 475 -p. 476, `Leucocyte Typing IV. White Cell Differentiation Antigens (Eds. W. Knapp et al.)` 1989, Oxford University Press, Oxford, GB.
J. Waugh et al., `Staining of normal or rejecting kidney using the activation panel`, p. 485 -p. 486, `Leucocyte Typing IV. White Cell Differentiation Antigens (Eds. W. Knapp et al.)` 1989, Oxford University Press, Oxford, GB.
N. Dunlap et al., `Expression of activation antigens on HTLV-I and HTLV-II cell lines`, p. 487 -p. 488, `Leucocyte Typing IV. White Cell Differentiation Antigens (Eds. W. Knapp et al.)` 1989, Oxford, GB.
R. Vilella et al., `Sequential appearance of the activation antigens`,p. 495 -p. 498, `Leucocyte Typing IV. White Cell Differentiation Antigens (Eds. W. Knapp et al.)` 1989, Oxford University Press, Oxford, GB.
G. Aversa et al., `Activation panel antigen expression on PBL activated by PHA or in MLR`, p. 498 -p. 501, `Leucocyte Typing IV. White Cell Differentiation Antigens (Ed. W. Knapp et al.)` 1989, Oxford University Press, Oxford, GB.
P. King et al., `Tonsillar dendritic-cell-induced T-lymphocyte proliferation: analysis of molecular mechanisms using the activation panel of mAb`, p. 503 -p. 505, `Leucocyte Typing IV. White Cell Differentiation Antigens (Eds. W. Knapp et al.)` 1989, Oxford University Press, Oxford, GB.
O. Rentrop et al., `Biochemical analysis of the Workshop antibodies of the activation section`, p. 473 -p. 474, `Leucocyte Typing IV. White Cell Differentiation Antigens (Eds. W. Knapp et al.)` 1989, Oxford University Press, Oxford, GB.
U. Latza et al., `The human OX40 homolog: cDNA structure, expression and chromosomal/assignment of the ACT35 antigen`, pp. 677 -683, European Journal of Immunology, vol. 24, No. 3, Mar. 1994, Weinheim, Germany.
W. Godfrey, et al. `Identification of a human OX-40 ligand, a costimulator of CD4+ T cells with homology to tumor necrosis factor`, pp. 757 -762, The Journal of Experimental Medicine, vol. 180, N0. 2, Aug. 1994, New York NY, USA.
W. Godfrey et al., `Stan-40, a new member of the FAS-TNFr superfamily expressed selectively on activated, human CD+ T cells`, p. 355, Journal of Cellular Biochemistry, Supplement, vol. 0, No. 18D, 1994, New York NY, USA.
Caldherhead, et al., "Cloning of Mouse OX40: A T Cell Activation Marker That May Mediate T-B Cell Interactions," J. Immun. 151:5261-5271 (1993).
Holoshitz, et al., "Arthritis Induced in Rats by Cloned T Lymphocytes Responsive to Mycobacteria but Not to Collagen Type II," J. Clin. Invest. 73:211-215 (1984).
Kennedy, et al., "Analysis of Cytokine mRNA Expression in the Central Nervous System of Mice with Experimental Autoimmune Encephalomyelitis Reveals that IL-10 mRNA Expression Correlates with Recovery , " J. Immun. 149:2496-2505 (1992).
Khoury, et al., "Oral Tolerance to Myelin Basic Protein and Natural Recovery from Experimental Autoimmune Encephalomyelitis Are Associated with Downregulation of Inflammatory Cytokines and Differential Upregulation of Transforming Growth Factor .beta., Interleukin 4, and Prostaglandin E Expression in the Brain," J. Exp. Med. 176:1355-1364 (1992).
Mallett, et al., "Characterization of the MRC OX40 Antigen of Activated CD4 Positive T Lymphocytes--a Molecule Related to Nerve Growth Factor Receptor," Embo J. 9:1063-1068 (1990).
Paterson, et al., "Antigens of Activated Rat T Lymphocytes Including a Molecule of 50,000M.sub.r Detected Only on CD4 Positive T Blasts," Mol. Immun. 24:1281-1290 (1987).
Steinman, Lawrence, "Autoimmune Disease," Sci. Amer. 9: 107-114 (1993).
Vitetta, et al., "Phase I Immunotoxin Trial in Patients with B-Cell Lymphoma," Cancer Res. 51:4052-4058 (1991).
Weinberg, et al., "Transforming Growth Factor-.beta. Enhances the in Vivo Effector Function and Memory Phenotype of Antigen-Specific T Helper Cells in Experimental Autoimmune Encephalomyelitis," J. Immun. 148:2109-2117 (1992).
Walmann, Monoclonal antibodies in diagnosis and therapy, Science, vol. 252, pp. 1657-1662, 1991.
Parker et al., Fusion Proteins in Immu notherapy, Trans. Proc. vol. 24, No. 6, pp. 2362-2365, 1992.
Emery et al. (Exp. Opin. Invest. Drugs, 1994.
Vandenbark Arthur A.
Weinberg Andrew D.
LandOfFree
Treatment of CD4 T-cell mediated conditions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of CD4 T-cell mediated conditions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of CD4 T-cell mediated conditions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1456617